Legend Biotech Corporation (LEGN) has a MoatMap StockRank of 49/100 based on Quality (32/100), Value (40/100), and Momentum (64/100) factor scores. The current signal is HOLD. Legend Biotech is a leader in cell therapy with its blockbuster Carvykti. However, cell therapy manufacturing is highly complex and currently bottlenecked. While it highlights the importance of advanced manufacturing, Legend is a biotech developer rather than a CDMO beneficiary, and its high valuation and capital needs do not offer the asymmetric risk-reward we seek.
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies, primarily CAR-T treatments for oncology. The company's core asset is Carvykti, a potentially transformative CAR-T therapy for multiple myeloma, developed in partnership with Janssen. Its competitive advantage lies in its proprietary cell therapy platform and advanced pipeline, positioning it as a leading innovator in the rapidly evolving and high-potential field of cellular immunotherapy.
| Price | $33.49 |
| Market Cap | $5.2B |
| P/E (Forward) | 25.62 |
| Price/Book | 6.56 |
| Return on Equity | -25.2% |
| Return on Invested Capital | -23.8% |
| Debt/Equity | 40.23 |
| Gross Margin | 20.0% |
| Operating Margin | -16.3% |
| Revenue Growth | 56.5% |
| Free Cash Flow | $-56M |
Legend Biotech Corporation operates in the Biotechnology industry, part of the Healthcare sector (United States).